Medical Management of Heart Failure
|
|
- Sharyl Bond
- 6 years ago
- Views:
Transcription
1 Medical Management of Heart Failure Louisville Symposium on Heart Disease in Women June 28, 2014 Andrew J. Lenneman, MD Assistant Professor of Medicine University of Louisville Division of Cardiovascular Medicine
2 Goals: Review guidelines based management for chronic heart failure therapy Discuss key trials used to develop heart failure treatment guidelines Discuss gender differences in heart failure
3 Heart Failure Deaths Slaughter, MS. Tex Heart Inst J, 2010
4 Women and Heart Failure Women are >50% of all CHF admissions CHF with preserved EF more common in women Nonischemic > Ischemic HTN, DM2, valvular disease HF associated depression is more common in women Unique causes: Peripartum cardiomyopathy Takotsubo cardiomyopathy Anthracycline induced cardiomyopathy
5 Women are under- represented in CHF trials Study Number of Women % Women MERIT- HF SOLVD Treatment SOLVD PrevenTon RALES EPHESUS DIG CIBIS II COPERNICUS CHARM - Overall CHARM - Preserved ELITE - II Val- HEFT COMPANION MIRACLE MUSTIC A- HEFT V- HEFT 0 0 CARE- HF
6 ~ 5-10% Hunt SA, et al. Circula(on 2001;104:
7 A Progression of Heart Failure Progression of Heart Failure B Arrhythmia CAD Diabetes Hypertension Cardiomyopathy Valvular disease Left ventricular injury Remodeling Low ejection fraction Death Pump failure neurohormonal swmulawon endothelial dysfuncwon vasoconstricwon renal sodium retenwon Non cardiac factors Symptoms Chronic heart failure Cohn JN; N EnglJ Med :490
8 IdenTfying the Stage B PaTent Echocardiography recommended for: CAD (ayer MI, revascularizawon) HTN, Valvular heart disease Family history of cardiomyopathy in 1 st degree relawve Atrial fibrillawon or flu_er EKG with LVH, LBBB, or pathologic Q waves Goals: Prevent progression to symptomawc disease Prevent death Maintain an excellent quality of life Do no harm Circulation 2013; 128:
9 Stage C The Symptoms of HF Symptoms Dyspnea on exerwon or at rest Declining exercise tolerance Orthopnea PND or nocturnal cough Edema Ascites or scrotal swelling Less specific presentatons Wheezing or cough Unexplained fawgue GI complaints: early sawety, nausea/ vomiwng, abdominal discomfort Depression/delirium (especially in elderly)
10 Stage C Guidelines: Medical Treatment of symptomatc Heart Failure Reduced EF ACE inhibitors/arbs Beta blockers DiureWcs Aldosterone antagonists ISDN+Hydralazine Digoxin ICD + CRT Preserved EF DiureWcs ACE inhibitors/arbs Beta blockers if MI, HTN, or AF? Aldosterone antagonists? Sildenafil? Ranolazine (TOPCAT) Think about restrictive diseases (amyloidosis, HCM) and constriction 2013 ACCF/AHA Guideline for the Management of Heart Failure Circula(on 2013; 128:
11 Improving Mortality in HF Trials 18 SOLVD SAVE 1991 CIBIS MERIT-HF 1999 SCD-HeFT % Death at 1 year DiureWcs, Digoxin DiureWcs, Digoxin, ACEi DiureWcs, Digoxin, ACEi, B- Blocker DiureWcs, Digoxin, ACEi, B- Blocker, ICD
12 ACE inhibitors/arb in Heart Failure Bradykinin System Kininogen Angiotensin System Angiotensinogen Renin Endothelium Bradykinin Angiotensin I + Prostaglandins Nitric oxide Inactive peptide + + ACE Angiotensin II Vasodilation Vasoconstriction! aldosterone Cell growth VanderbiltHeart.com
13 ACEi: Does dose maaer? The ATLAS trial TABLE 2. Effect of Treatment on Major Clinical Events Low-Dose High-Dose Hazard Ratio P All-cause mortality 717 (44.9) 666 (42.5) 0.92 ( ) Cardiovascular mortality 641 (40.2) 583 (37.2) 0.90 ( ) All-cause mortality hospitalization for any reason 1338 (83.8) 1250 (79.7) 0.88 ( ) All-cause mortality hospitalization for cardiovascular reason 1182 (74.1) 1115 (71.1) 0.92 ( ) All-cause mortality hospitalization for heart failure* 964 (60.4) 864 (55.1) 0.85 ( ) Cardiovascular mortality hospitalization for cardiovascular reason 1161 (72.7) 1088 (69.4) 0.91 ( ) Fatal and nonfatal myocardial infarction hospitalization for unstable angina 224 (14.0) 207 (13.2) 0.92 ( ) Values in parentheses indicate percentage or range. P values determined by log-rank test. Hazard ratios represent 95% CI, except for all-cause mortality, shown as 96.1% CI. *Analysis not specified in protocol before breaking the blind. Some is better than none Packer M et al. CirculaTon 1999;100:
14 ACE Inhibitors in Heart Failure Key points Start low dose, up- Wtrate to target doses from trials Check K+, creawnine within 1-2 weeks of each dose increase Minimize coincident ASA dose in nonischemics ContraindicaTons: Hx of life- threatening adverse effects Hypotension CreaWnine >3 g/dl Bilateral renal artery stenosis K+ 5.5 mmol/l
15 When to use ARBs in Heart Failure ACC/AHA Guidelines: Use as an alternawve when an ACEi is not tolerated (Class I) cough or angioedema Titrate dose similar to ACEi Evidence is mixed for ACEi + ARB CHARM- added vs. VALIANT Hypotension, worsening renal funcwon, hyperkalemia (Just like ACEi) Circulation. 2013;128:
16 Beta Blockers in Heart Failure How do Beta- Blockers Improve Heart Failure? UpregulaWon of beta receptors Improved coupling of beta receptors to intracellular signals AlteraWons in myocardial metabolism Improved calcium transport Increased protein synthesis and message expression InhibiWon of renin- angiotensin system InhibiWon of endothelin and cytokine release
17 Beta Blockers and Mortality in SAVE The best survival occurred with a Combination of ACE inhibitors And beta blockers Beta Blocker n=2231 pts Yes No Yes 13.3% 24.3% ACEi No 19.5% 27.7% N Engl J Med 1992 Sep 3;327:669-77
18 Outcome Trials of Beta Blockers in Heart Failure Trial Name Agent NYHA class % II/III/IV Hazard rato US carvedilol carvedilol 52/44/ CIBIS- II bisoprolol 0/83/ MERIT- HF metoprolol 41/56/ COPERNICUS carvedilol "severe" 0.65
19 . Beta Blockers in CHF: Does Dose Maaer? Bristow M R et al. Circulation 1996;94:
20 Beta Blockers in Heart Failure Key points Guidelines favor use of carvedilol, metoprolol succinate, bisoprolol Start at low dose, slowly up- Wtrate Aim to achieve target dose in 8-12 weeks Delay starwng if significant volume overload or hypovolemia/shock RelaWve contraindicawons: ReacWve airway disease, bradycardia, DM with recurrent hypoglycemia, reswng limb ischemia
21 DiureTcs in Heart Failure Rapidly improve symptoms of congeswon and lower cardiac filling pressures Deleterious Effects: AcWvate sympathewc nervous system and RAAS Electrolyte disturbances Decrease Cardiac output and GFR DiureWc resistance can be a marker of disease progression Don t forget about dietary sodium restricwon
22 JACC Vol. 59, No. 24, 2012
23 Aldosterone Antagonists N Probability of Survival R RALES- Advanced HF NYHA class III- IV LVEF<35% Months Spironolactone N EnglJ Med :709 Placebo Hospitalization for Heart Failure or Death from Cardiovascular Causes (%). at Risk EMPHASIS- HF NYHA class II Hazard ratio, 0.63 (95% CI, ) P<0.001 Placebo Years since Randomization Eplerenone N Engl J Med Jan 6;364(1):11-21
24 Aldosterone Antagonists Key Points NYHA class II- IV pawents with LVEF<35% Consider in most pawents with class II- IV CHF Following acute MI, with clinical HF or DM2 AND LVEF <40% (EMPHASIS- POST MI) K monitoring should be more rigorous in pawents at risk of hyperkalemia ContraindicaWons: Cr>2.5 mg/dl, K>5.0 mmol/l, elderly or cachewc pawents
25 Digoxin use in Heart Failure 50 Mortality from Any Cause (%) Placebo Digoxin P Months Overall Mortality The Digitalis Investigation Group: N EnglJ Med 336:525, 1997
26 30-d ay all-cause hospit tal admission Digoxin use in Heart Failure Number at risk Hazard ratio=0.66; 95% CI= ; p=0.002 Placebo Digoxin Follow-up p( (days) American Journal of Medicine (March 2013)
27 Digoxin use in Heart Failure No difference in mortality: serum level DIG trial Digoxin decreases hospitalizawons for CHF DIG trial Digoxin withdrawal results in worsening symptoms and exercise tolerance despite ACEIs RADIANCE Trial; PROVED Trial
28 What about Nitrates + Hydralazine? For pawents who develop hyperkalemia or renal dysfuncwon with ACE- I or ARB s Can be used IN ADDITION to ACE- I and β- blocker therapy in African- American pawents who have persistent NYHA class II- IV symptoms Overall Survival (%) No. at Risk Placebo Isosorbide dinitrate plus hydralazine P= Isosorbide dinitrate plus hydralazine Placebo Days since Baseline Visit N Engl J Med 2004;351: Circulation 2009, 119:e391-e479
29 HF management: More than just Drugs! Acute or chronic, reduced or normal EF NutriWonal counseling Sodium restricwon Fluid restricwon Alcohol Daily weights, symptom assessment, acwon plan Regular physical acwvity Compliance PaWents and family caregivers receive individualized educawon and counseling Frequent reinforcement emphasizing self care Early hospital follow up clinic + phone calls Cardiac Rehab/exercise training
30 Drugs to Avoid in Heart Failure NSAIDS Most anwarrhythmics Most Calcium channel blockers Felodipine, amlodipine are likely safe Thiazolidinediones Pioglitazone, rosiglitazone OTC Cold medicawon
31 Gender analysis of HF therapies Table 3. Effect of ACE Inhibitors on Mortality From Heart Failure in Male and Female Patients Reported Separately for Prevention Studies and Treatment Studies Analysis RR Male (95% CI) RR Female (95% CI) RRR (95% CI) Treatment (symptomatic) studies 0.80 ( ) 0.90 ( ) 1.15 ( ) Prevention (asymptomatic) studies 0.83 ( ) 0.96 ( ) 1.25 ( ) Abbreviations as in Table 2. RR Analysis Study-Name Total N Male N Female N RR Male (95% CI) RR Female (95% CI) CIBIS-II 2,647 2, ( ) 0.52 ( ) COPERNICUS 2,287 1, ( ) 0.63 ( ) MERIT-HF 3,991 3, ( ) 0.93 ( ) U.S. Carvedilol HF 1, ( ) 0.32 ( ) Random effects pooled estimate 7,885 2, ( ) 0.63 ( ) Abbreviations as in Table 2. Trial acronyms as in Abbreviation Box. J Am Coll Cardiol 2003;41:
32 Primary PrevenTon of Sudden Cardiac Death SCD-HeFT trial Placebo vs. Amio vs. ICD 0.4 Amiodarone vs. placebo ICD therapy vs. placebo Hazard Ratio (97.5% CI) 1.06 ( ) 0.77 ( ) P Value % Placebo (244 deaths; 5-yr event rate, 0.361) Mortality Rate Amiodarone (240 deaths; 5-yr event rate, 0.340) 34% ICD therapy (182 deaths; 5-yr event rate, 0.289) 29%, p No. at Risk Months of Follow-up Bardy N Engl J Med 2005;352:225-37
33 Primary PrevenTon of Sudden Cardiac Death in Heart Failure: ICD Consider ICD in all pawents with EF 35% with mild to moderate symptoms (NYHA II- III) Use cauwon in pawents with chronic, severe symptoms (NYHA IV) and life expectancy < 1 yr MADIT II, COMPANION, SCDHeFT all improve mortality ICDs are cost effecwve ($33,192/ life year added) 2013 ACCF/AHA Guideline for the Management of Heart Failure Circula(on 2013; 128:
34 Cardiac ResynchronizaTon Therapy Recommended for pawents with: Sinus rhythm on OMM QRS 120 ms (LBBB > RBBB) EF 35% NYHA III and ambulatory NYHA IV NYHA II, EF <30%, QRS>130 Improves funcwonal capacity Improves ventricular funcwon ( LVEF, EDD) Decreases hospitalizawons BiV pacing + ICD confers mortality benefit 2013 ACCF/AHA Guideline for the Management of Heart Failure Circula(on 2013; 128:
35 Chronic Heart Failure Management Take Home Points OpWmal medical and electrical therapy has improved survival considerably in heart failure Women are underrepresented in CHF trials but benefit from guidelines based treatments IdenWficaWon of the high risk pawent with heart failure is important to offer Wmely life saving intervenwons Use highest tolerated doses of Neurohormonal bockade a li_le is be_er than none CHF management is more than just drugs To have a global impact on the outcomes of heart failure, prevenwon and treatment of risk factors is be_er than a cure
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationMEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationAll in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationSara O. Weiss, MD Director, Heart Failure Services Virginia Mason Medical Center September 8, 2012
Sara O. Weiss, MD Director, Heart Failure Services Virginia Mason Medical Center September 8, 2012 Disclosure: Dr. Weiss has no significant financial interest in any of the products or manufacturers mentioned.
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationHeart Failure. Dr. William Vosik. January, 2012
Heart Failure Dr. William Vosik January, 2012 Questions for clinicians to ask Is this heart failure? What is the underlying cause? What are the associated disease processes? Which evidence-based treatment
More informationCongestive Heart Failure 2015
Definition Congestive Heart Failure 215 JP Mehegan/ Mercy Cardiology n Cardiac failure; Congestive heart failure; Chronic heart failure (synonyms) n When the heart is unable to pump sufficiently and at
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationHeart Failure. Jay Shavadia
Heart Failure Jay Shavadia Definition Clinical syndrome characterized by: Symptoms: breathlessness at rest or on exercise, fatigue, tiredness or ankle swelling AND Signs: tachycardia, tachypnea, pulmonary
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationImpact of the African American Heart Failure Trial (A-HeFT): Guideline-based Therapy in Blacks with Heart Failure 2016
Impact of the African American Heart Failure Trial (A-HeFT): Guideline-based Therapy in Blacks with Heart Failure 2016 National Minority Quality forum APRIL 11, 2016 Washington,D.C. Keith C. Ferdinand,
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center March 2014 Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationHeart Failure Management Update
Heart Failure Management Update Rafique Ahmed, MD, PhD, FACC, FCPS Consultant Cardiac Electrophysiologist Baltimore, Maryland, USA Heart Failure - Definition The situation when the heart is incapable of
More informationCardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital
More informationNora Goldschlager, M.D. SFGH Division of Cardiology UCSF
CLASSIFICATION OF HEART FAILURE Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF DISCLOSURES: NONE CLASSIFICATION C OF HEART FAILURE NYHA I IV New paradigm Stage A: Pts at high risk of developing
More informationEpidemiology of Symptomatic Heart Failure in the U.S.
William T. Abraham, MD, FACP, FACC, FAHA, FESC Professor of Medicine, Physiology, and Cell Biology Director, Division of Cardiovascular Medicine Deputy Director Davis Heart and Lung Research Institute
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR
ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationHeart Failure New Drugs- Updated Guidelines
Heart Failure New Drugs- Updated Guidelines Eileen Handberg, PhD, ANP-BC, FAHA, FACC Professor of Medicine Division of Cardiovascular Medicine University of Florida Disclosures 1. 3 2. 6 3. 8 4. 11 Dunlay
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationHeart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid
Failure? blood supply insufficient for body needs CHF = congestive heart failure increased blood volume, interstitial fluid Underlying causes/risk factors Ischemic heart disease (CAD) 70% hypertension
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationWomen s Heart Health: Holistic Approaches Throughout the Lifetime - Key Differences in Heart Failure in Women
Women s Heart Health: Holistic Approaches Throughout the Lifetime - Key Differences in Heart Failure in Women C. Noel Bairey Merz MD Medical Director and Barbra Streisand Women s Heart Center Preventive
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationRecently, much effort has been put into research. Advances in... Congestive Heart Failure Care. How is CHF diagnosed? 2.
Advances in... Congestive Heart Failure Care Heart failure can currently be considered an epidemic. The article discusses some of the recent advances in outpatient management of congestive heart failure.
More informationChronic. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Michael G. Shlipak, MD, MPH
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationHeart Failure in Women
Heart Failure in Women Disclosure Professor Sindone has received honoraria, speaker fees, consultancy fees, is a member of advisory boards or has appeared on expert panels for: Professor Andrew Sindone
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationEstimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches
Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder
More informationThe Therapeutic Potential of Novel Approaches to RAAS. Professor of Medicine University of California, San Diego
The Therapeutic Potential of Novel Approaches to RAAS Inhibition in Heart Failure Barry Greenberg, M.D. Professor of Medicine University of California, San Diego Chain of Events Leading to End-Stage Heart
More informationCardiovascular Clinical Practice Guideline Pilot Implementation
Cardiovascular Clinical Practice Guideline Pilot Implementation Pharmacologic Management of Chronic Heart Failure Sept 15, 2004 Angela Allerman, PharmD, BCPS DoD Pharmacoeconomic Center Promoting high
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationHeart Failure Dr Eric Klug Sunninghill, Sunward Park, CM Johannesburg Academic Hospital
Heart Failure 2012 Dr Eric Klug Sunninghill, Sunward Park, CM Johannesburg Academic Hospital PRELOAD COWS Reduction in milk production INOTROPY & HEART RATE AFTERLOAD DISTRIBUTION NETWORK THE CLASSIC APPROACH
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationheart failure John McMurray University of Glasgow.
A to Z of RAAS blockade in heart failure John McMurray BHF Cardiovascular Research Centre University of Glasgow. RAAS inhibition in CHF ACE inhibition in patients with low LVEF CHF CONSENSUS Enalapril
More informationFaiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm
Faiez Zannad Institut Lorrain du Coeur et des Vaisseaux CIC - Inserm Disclosure Faiez Zannad Grants BG Medicine, Roche Diagnostics. Consultant/Steering committees/event committees/ Data safety Monitoring
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationUpdate in Congestive Hear Failure DRAGOS VESBIANU MD
Update in Congestive Hear Failure DRAGOS VESBIANU MD Case 58 yo AAM c/o shortness of breath for 3 weeks. Used to walk one mile per day and now he has noticed that he gets short of breath after 2 blocks.
More informationUpdate on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy
Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationTranslating Evidence Based Recommendations Into Practice
Pharmacotherapy in Chronic Heart Failure: Translating Evidence Based Recommendations Into Practice Jennifer Ballard Hernandez MSN, RN, FNP BC/GNP BC, CCRN CSC, AACC Nurse usepractitioner, actto e, Heart
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationLITERATURE REVIEW: HEART FAILURE. Chief Residents
LITERATURE REVIEW: HEART FAILURE Chief Residents Heart Failure EF 40% HFrEF Problem with contractility EF 40-50% HFmrEF EF > 50% HFpEF Problem with filling/relaxation RISK FACTORS Post MI HTN DM Obesity
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More informationLa stimulation biventriculaire (Traitement par Resynchronisation Cardiaque) Indications et Résultats. Daniel Gras, DIU, Paris 2007
La stimulation biventriculaire (Traitement par Resynchronisation Cardiaque) Indications et Résultats, DIU, Paris 2007 CRT: Results and indications Background Results of CRT Studies Today s classical CRT
More informationOptimal Adrenergic Blockades in Heart Failure. Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea
Optimal Adrenergic Blockades in Heart Failure Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea Contents Harmful effects of adrenergic system in heart failure Clinical studies
More informationHeart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis. More malignant than most cancers
Patients in US (millions) Heart Failure (HF): Scope of the Problem 1 4 2 3.5 4. 1. 1991 21 237 US prevalence*: 5. million US annual incidence: 7, Annual mortality: 22,754 5-1% depending on severity Cost:
More informationGuidelines for the Treatment of HEART FAILURE
Guidelines for the Treatment of HEART FAILURE Leslie W. Miller University of Minnesota HEART FAILURE Facts 5 million patients with CHF in U.S. 55, new cases/year 3, deaths/year 4 fold increase in risk
More informationIncidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction
Heart Failure Diagnosis According to the Working Group in Heart Failure, CHF is a syndrome where the diagnosis has the following essential components: A combination of: Symptoms, typically breathlessness
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationBeta-blockers in heart failure: evidence put into practice
Beta-blockers in heart failure: evidence put into practice John McMurray Professor of Medical Cardiology, University of Glasgow & Consultant Cardiologist,Western Infirmary, Glasgow, UK Eugene Braunwald
More informationRisk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationContemporary Advanced Heart Failure Therapy
Contemporary Advanced Heart Failure Therapy Andrew Boyle, MD Professor of Medicine Medical Director of Advanced Heart Failure Thomas Jefferson University Philadelphia, PA Audience Response Question 40
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationI have no disclosures. Disclosures
I have no disclosures Disclosures What is Heart Failure? Heart Failure (HF) A complex clinical syndrome where patients present with symptoms (i.e. dyspnea, fatigue, fluid retention) that result from any
More informationNew Strategies For Treating Patients With Chronic Heart Failure
New Strategies For Treating Patients With Chronic Heart Failure Barry Greenberg MD Professor of Medicine Director, Advanced Heart Failure Treatment Program University of California, San Diego Disclosures
More informationOutline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies
Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the
More informationManagement of Heart Failure in Older Adults
Management of Heart Failure in Older Adults New Data, New Guidelines, New Challenges JOSE NATIVI, MD, MSCI Assistant Professor of Medicine Cardiovascular Director Amyloidosis Program DISCLOSURES - Advisory
More informationHF and CRT: CRT-P versus CRT-D
HF and CRT: CRT-P versus CRT-D Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief, Cardiology Section Philadelphia VA Medical Center Philadelphia, PA
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationPathophysiology: Heart Failure
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationUCLA HEART FAILURE CLINICAL PRACTICE GUIDELINE SUMMARY-2004
UCLA HEART FAILURE CLINICAL PRACTICE GUIDELINE SUMMARY-2004 Ahmanson-UCLA Cardiomyopathy Center UCLA Medical Center Los Angeles, California Gregg C. Fonarow, MD, Director Ahmanson-UCLA Cardiomyopathy Center
More informationOutline. Chronic Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center Scientific
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationHeart Failure Management Policy and Procedure Phase 1
1301 Punchbowl Street, Harkness Suite 225 Honolulu, Hawaii 96813 Phone (808) 691-7220 Fax: (808) 691-4099 www.queenscipn.org Policy and Procedure Phase 1 Policy Number: Effective Date: Revised: Approved
More informationOptimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists
Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists Old Drugs for an Old Problem Jay Geoghagan, MD, FACC BHHI Primary Care Symposium February 28, 2014 None. Financial disclosures
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationContemporary Management of Heart Failure. Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium
Contemporary Management of Heart Failure Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium Disclosures I have no relevant relationships with commercial
More informationUpdates in Diagnosis & Management of CHF
Updates in Diagnosis & Management of CHF N. Goldberg, DO April 30, 2011 CHF CHF is reaching an epidemic level in U.S. and continues to worsen over time Reasons are: HTN Dm with sedentary lifestyle and
More informationCHF is a clinical syndrome in which heart failure is accompanied by symptoms and signs of pulmonary and/or peripheral congestion
Congestive Heart Failure Lokesh Tejwani, MD Heart Failure A patho-physiological state in which abnormality of cardiac function is responsible for failure of the heart to pump blood at a rate commensurate
More information